What one share of Perspective Therapeutics holds
We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Perspective Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.25 |
|---|---|
| Capex (buildings and equipment) | $0.30 |
| Free cash flow | −$1.30 |
| Cash and investments | $0.42 |
| Debt | $0.01 |
| Book value | $2.84 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | $2.08 | −$1.10 | $0.05 | −$1.02 | — | $2.44 |
| 2012 | $1.77 | −$1.22 | $0.02 | −$0.87 | — | $1.88 |
| 2013 | $1.31 | −$1.12 | $0.00 | −$0.89 | — | $1.55 |
| 2014 | $0.99 | −$1.57 | $0.00 | −$0.76 | — | $4.38 |
| 2015 | $0.84 | −$0.70 | $0.02 | −$0.67 | — | $3.78 |
| 2016 | $0.87 | −$0.90 | $0.09 | −$0.79 | — | $2.98 |
| 2017 | $0.87 | −$1.12 | $0.10 | −$1.14 | — | $1.93 |
| 2018 | $1.07 | −$1.22 | $0.06 | −$1.10 | — | $0.89 |
| 2019 | $1.09 | −$0.80 | $0.07 | −$0.82 | — | $1.14 |
| 2020 | $1.43 | −$0.51 | $0.04 | −$0.58 | — | $0.83 |
| 2021 | $0.97 | −$0.30 | $0.04 | −$0.31 | — | $4.75 |
| 2022 | $0.76 | −$0.51 | $0.02 | −$0.56 | — | $4.31 |
| 2022 | $0.00 | −$0.76 | $0.02 | −$0.75 | — | $3.85 |
| 2023 | $0.05 | −$1.74 | $0.04 | −$1.42 | — | $2.67 |
| 2024 | — | −$1.23 | $0.84 | −$1.13 | — | $4.11 |
| 2025 | — | −$1.40 | $0.17 | −$1.29 | — | $2.79 |
Common questions about Perspective Therapeutics
How much does one share of Perspective Therapeutics earn?
Over the last 12 months, Perspective Therapeutics lost $1.25 for each share.
Does Perspective Therapeutics pay a dividend?
Perspective Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Perspective Therapeutics’s book value per share?
Perspective Therapeutics’s book value is $2.84 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Perspective Therapeutics have?
Each share of Perspective Therapeutics has $0.42 of cash and investments and $0.01 of debt, as of June 30, 2026.
What is Perspective Therapeutics’s free cash flow per share?
−$1.30 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Perspective Therapeutics bought back shares?
Perspective Therapeutics’s share count rose about 2837% from 2011 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.